An update on prognosis in breast cancer patients with extensive axillary disease

Breast Journal

Volumn 14, Issue 1, 2008, Pages 76-80

  Hoehne, Francesca ^a   Chen, Steven ^a   Mabry, Helen ^a   Giuliano, Armando E ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

10 lymph nodes; Anthracycline; Breast cancer; Estrogen receptor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LOCAL THERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SYSTEMIC THERAPY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 37849000481     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00517.x     Document Type: Article

References (34)

1. Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003 237 : 732 9.
2. Nemoto T, Vana J, Bedwani R, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980 45 : 2917 24.
3. Bonadonna G, Valagussa P. Dose-response of adjuvant chemotherapy in breast cancer. N Engl J Med 1981 304 : 10 5.
4. Fisher B, Montague E, Redmond C, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968 168 : 337 56.
5. Fisher B, Bauer M, Wickerham L, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983 52 : 1551 7.
6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989 63 : 181 7.
7. Duraker N, Caynak ZC. Prognostic value of the 2002 TNM classification of breast carcinoma with regard to the number of metastatic axillary lymph nodes. Cancer 2005 104 : 700 7.
8. Faneyte IF, Peterse JL, van Tinteren H, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004 10 : 4457 63.
9. Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 1992 69 : 448 52.
10. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2003 100 : 44 52.
11. Montero AJ, Rouzier R, Lluch A, et al. The natural history of breast carcinoma in patients with ≥10 axillary lymph nodes before and after the advent of adjuvant therapy. Cancer 2005 104 : 229 35.
12. Moon TE, Jones SE, Bonadonna G, et al. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 1987 10 : 396 403.
13. Day RS, Shackney SE, Peters WP. The analysis of relapse-free survival curves: implication for evaluating intensive systemic adjuvant treatment regimens for breast cancer. Br J Cancer 2005 92 : 47 54.
14. Walker MJ, Osborne MD, Young DC, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg 1995 169 : 575 9.
15. Gann PH, Colilla SA, Gapstur SM, et al. Factors associated with axillary lymph node metastasis from breast carcinoma. Cancer 1999 86 : 1511 9.
16. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003 97 : 545 53.
17. Neri A, Marrelli D, Roviello F, et al. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Onc 2005 12 : 246 53.
18. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003 98 : 2133 43.
19. Park BW, Kim SI, Kim EY, et al. Impact of patient age on the outcome of primary breast carcinoma. J Surg Oncol 2002 80 : 12 8.
20. Ayash LJ, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996 14 : 2984 92.
21. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997 15 : 2312 21.
22. Rodenhuis S, Richel D, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998 352 : 515 21.
23. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000 92 : 225 33.
24. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002 13 : 689 98.
25. Leonard RCF, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004 96 : 1076 83.
26. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004 22 : 2273 83.
27. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005 23 : 2191 200.
28. Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005 3 : CD003142.
29. Jabro G, Wazer DE, Ruthazer R, et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with ≥10 positive axillary nodes. Int J Radiat Oncol Biol Phys 1999 44 : 273 80.
30. Trocciola SM, Hoda S, Osborne MP, et al. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? J Am Coll Surg 2005 200 : 720 6.
31. Yu JJ, Brennan M, Christos P, et al. Bone marrow micrometastases and adjuvant treatment of breast cancer. Breast J 2004 10 : 181 5.
32. Schindlbeck C, Kampik T, Janni W, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 2005 7 : 1174 85.
33. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006 98 : 262 72.
34. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005 11 : 8623 31.